PNC Financial Services Group
ATRA icon

PNC Financial Services Group’s Atara Biotherapeutics ATRA Stock Holding History

PNC Financial Services Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$30 – 4697
2023
Q4 		$30 Buy
+2
New +$47 ﹤0.01% 4589
2023
Q2 		– Sell
-2
Closed -$142 – 4735
2023
Q1 		$142 Hold
2
– – ﹤0.01% 4625
2022
Q4 		$161 Hold
2
– – ﹤0.01% 4656
2022
Q3 		$0 Buy
+2
New +$225 ﹤0.01% 4439
2018
Q2 		– Sell
-1
Closed -$2K – 4134
2018
Q1 		$2K Hold
1
– – ﹤0.01% 4020
2017
Q4 		$0 Buy
+1
New +$369 ﹤0.01% 4138
2016
Q3 		– Sell
-263
Closed -$148K – 3979
2016
Q2 		$148K Buy
263
+259
+6,475% +$124K ﹤0.01% 2257
2016
Q1 		$2K Hold
4
– – ﹤0.01% 4148
2015
Q4 		$2K Hold
4
– – ﹤0.01% 4135
2015
Q3 		$3K Buy
+4
New +$4.88K ﹤0.01% 4121

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

PNC Financial Services Group's ATRA Position: Q1 2024 in Review

PNC Financial Services Group sold out of Atara Biotherapeutics (ATRA) in Q1 2024, closing a stake of 2 shares — an estimated $30 sold.

PNC Financial Services Group first reported a position in ATRA in Q3 2015 and held it in 10 quarters. The position peaked at $148K in Q2 2016. 82 funds tracked by Wall St. Rank hold ATRA as of Q1 2024.

  • PNC Financial Services Group reported no remaining Atara Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • PNC Financial Services Group sold 2 Atara Biotherapeutics shares in Q1 2024, an estimated $30.
  • PNC Financial Services Group first reported a position in Atara Biotherapeutics in Q3 2015 and held it in 10 quarters.
  • PNC Financial Services Group's Atara Biotherapeutics position peaked at $148K in Q2 2016.
  • 82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2024.

Based on PNC Financial Services Group's 13F filing for Q1 2024, filed 10 May 2024.